Lexicon Pharmaceuticals (LXRX) Q4 2024 earnings summary

Executive summary

• Advanced pilavapadin for DPNP, sotagliflozin for HCM, and LX9851 for obesity, with pilavapadin 10 mg dose meeting phase 2b objectives and moving to Phase 3 in 2025.

• Strategic repositioning included ceasing all INPEFA promotion, reducing workforce by 70%, and focusing resources on clinical and business development.

• Secured a $25 million upfront payment from Viatris for sotagliflozin licensing outside the US/EU, with future milestone and royalty potential.

• Continued Phase 3 enrollment for sotagliflozin in HCM and advanced LX9851 toward IND filing in 2025.

• Published new data on sotagliflozin's cardiovascular benefits in The Lancet.

Financial highlights

• Ended 2024 with $238 million in cash and investments, up from $170 million at end of 2023.

• Q4 2024 revenue was $26.6 million; full-year 2024 revenue reached $31.1 million, driven by INPEFA sales and Viatris licensing payment.

• Q4 2024 net loss was $33.8 million ($0.09/share), improved from $49.8 million ($0.20/share) in Q4 2023; full-year net loss was $200.4 million ($0.63/share), up from $177.1 million ($0.80/share) in 2023.

• R&D expenses rose to $26.7 million in Q4 and $84.5 million for 2024; SG&A expenses for 2024 were $143.1 million.

• Operating expenses for 2024 were $228.2 million; long-term debt at year-end was $100.3 million.

Outlook and guidance

• 2025 operating expenses expected at $135–145 million; R&D $100–105 million; SG&A $35–40 million.

• Guidance excludes pilavapadin Phase 3 trial costs; pivotal trials to be planned after FDA meeting in H2 2025.

• Multiple 2025 catalysts anticipated, including full PROGRESS data for pilavapadin and IND filing for LX9851.

• Sonata HCM study targeting final results by end of 2026, with FDA filing expected in Q1 2027.

• All sites for SONATA HCM Phase 3 trial to be operational by Q3 2025.